Find an Article

Filter articles

Showing 1 to 10 of 447 results

Making a splash in the CRISPR patent pool

US15-09-2017Kevin O’Connor

With discussions underway to create a CRISPR patent pool, Kevin O’Connor of Neal, Gerber & Eisenberg discusses the three main perspectives when considering the main benefits of such a move.

Data analysis: the highs and lows of generic-filed IPRs

US30-08-2017Wenhua Yu, Stephen Maebius and Tianran Yan

Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan.

The innovation paradox: why complex drug research is not being rewarded

EU, US12-07-2017

The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law.

Precision medicine: getting patenting spot on

US12-07-2017Sheena Linehan

Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson.

Going it alone: possible outcomes for life sciences

EU, UK10-07-2017

With the two-year Brexit negotiations underway, life sciences companies and their lawyers will be watching closely to see how their businesses and IP will be affected. LSIPR reports with views from the UK, France and Germany.

The global CRISPR battleground


With legal developments in the CRISPR field ramping up this year, LSIPR examines the current international landscape and the options for parties interested in using the gene-editing technology.

GQ Life Sciences: searching for sequence IP


The products made by GQ Life Sciences, based in Boston, make IP-related sequence searching easier for scientists, patent searchers and practitioners, as senior product manager Ellen Sherin tells LSIPR.

The quest for clarity continues

EU, UK05-07-2017

The English High Court is seeking answers from the CJEU on aspects of the EU’s regulation on supplementary protection certificates, but it’s possible questions will remain following the rulings. Michael Pears and Joel Beevers of Potter Clarkson report.

Stem cells in Costa Rica: a boost for medical research

Costa Rica04-07-2017

Now that Costa Rica has allowed adult stem cells to be used as part of regenerative therapies, the country should be able to attract more investment, say María del Pilar López and Esteban Monge of Zürcher Lawyers.

Gene therapies in Mexico: bringing the legal framework up to speed


Despite their great ability to fight diseases, gene therapies face tough challenges from an IP and regulatory perspective in Mexico, as Hector Chagoya and Mariana Gonzalez of Becerril, Coca & Becerril report.

Showing 1 to 10 of 447 results